The full results of the trial stopped for futility in November 2025: 14,194 patients within 7 days of an ACS with at least two risk factors, milvexian 25 mg twice daily or placebo on top of antiplatelet therapy, median 10 months. Cardiovascular death, MI or ischaemic stroke 5.4 versus 5.1 percent (HR 1.05, 95% CI 0.91 to 1.21, p=0.50); BARC 3c or 5 bleeding 0.3 percent in both arms (HR 1.04). Presented by Gabriel Steg in Hot Line 3, NEJM. LIBREXIA AF and LIBREXIA Stroke continue.
